Interferon regulatory factors (IRFs) regulate transcription of interferon genes through DNA sequence-speci®c binding to these targets. Using a dierential display method for examining gene expression in p53-defective cells infected with adenovirus containing wild-type p53, we found that expression of interferon regulatory factor 5 (IRF-5) mRNA was increased in the presence of exogenous p53. An electrophoretic mobility-shift assay showed that a potential p53 binding site (p53BS) detected in exon 2 of the IRF-5 gene could in fact bind to p53 protein. Moreover, a heterologous reporter assay revealed that the p53BS possessed p53-dependent transcriptional activity. Expression of IRF-5 was induced in p53+/+ cells (MCF7 and NHDF), but not in p537/7 cells (H1299) when DNA was damaged by girradiation, UV-radiation, or adriamycin treatment in a wild-type p53-dependent manner. These results suggest that IRF-5 is a novel p53-target, and that it might mediate the p53-dependent immune response.
Interferon regulatory factors (IRFs) regulate transcription of interferon genes through DNA sequence-speci®c binding to these targets. Using a dierential display method for examining gene expression in p53-defective cells infected with adenovirus containing wild-type p53, we found that expression of interferon regulatory factor 5 (IRF-5) mRNA was increased in the presence of exogenous p53. An electrophoretic mobility-shift assay showed that a potential p53 binding site (p53BS) detected in exon 2 of the IRF-5 gene could in fact bind to p53 protein. Moreover, a heterologous reporter assay revealed that the p53BS possessed p53-dependent transcriptional activity. Expression of IRF-5 was induced in p53+/+ cells (MCF7 and NHDF), but not in p537/7 cells (H1299) when DNA was damaged by girradiation, UV-radiation, or adriamycin treatment in a wild-type p53-dependent manner. These results suggest that IRF-5 is a novel p53-target, and that it might mediate the p53-dependent immune response. Oncogene (2002) 21, 2914 ± 2918. DOI: 10.1038/sj/ onc/1205459 Keywords: IRF5; p53; target gene The p53 gene is considered to be the most important of all tumor suppressor genes, because nearly half of all human cancers examined are found to contain p53 mutations (Greenblatt et al., 1994) . The gene product is a transcription factor that binds to speci®c DNA sequences to activate transcription of target genes (Levine, 1997) . Numerous p53-targets have been isolated and characterized to date. Among them, p21/ WAF1 and BAX are thought to be the most important because their products mediate two major functions of p53, cell-cycle arrest and apoptosis respectively (Harper et al., 1993; el-Deiry et al., 1993; Miyashita and Reed, 1995) . Moreover, given that many p53-target genes have been reported and that more than 100 potential binding sites for p53 are present in the human genome (Tokino et al., 1994) , we suspect that p53 is likely to achieve tumor suppression by regulating the physiological functions of not a few, but multiple genes. To clarify the precise mechanisms of p53 tumor suppression, identi®cation of additional target genes would seem to be an absolute requirement.
In past experiments we succeeded in isolating several p53-target genes using two dierent methods. One method involved dierential display using a cell line in which expression of an exogenous wild-type p53 gene can be regulated under the control of the lactose operon (Takei et al., 1998) . In this manner we isolated four novel genes, TP53TG1 (Takei et al., 1998 ), TP53TG3 (Ng et al., 1999 , p53R2 , and p53DINP1 (Okamura et al., 2001) , as direct targets of p53. p53R2 is commonly involved in p53-dependent DNA repair in response to diverse agents of DNA damage , while p53DINP1 mediates the p53-dependent apoptotic pathway (Okamura et al., 2001) . Our second method was to employ a yeast enhancer-trap system that allowed direct cloning of functional p53-binding sequences from human genomic DNA (Tokino et al., 1994) . We isolated and sequenced cosmid clones containing every p53-binding site, and then searched for candidate genes in the genomic regions surrounding those binding sequences. With that method we isolated ®ve novel genes: GML, which contributes to the sensitivity of cells to anticancer drugs (Furuhata et al., 1996) ; P2XM , BAI1, which inhibits angiogenesis in gliomas ; CSR (Han et al., 1998) ; and p53AIP1, a pivotal mediator of p53-induced apoptosis (Oda et al., 2000) . These results suggested that p53 might have multiple physiological functions, by virtue of its ability to activate transcription of so many dierent genes.
To isolate novel p53-target genes we applied a dierential display method using mRNAs isolated from p53-de®cient U373MG cells (glioblastoma, the American Type Culture Collection, Manassas, VA, USA) infected by either Ad-p53 or Ad-LacZ. This strategy had previously shown that the fractalkine gene was a direct target of p53 . A DNA fragment corresponding to one of the bands that showed a stronger intensity in p53-transfected cells than in the LacZ-transfected cells was excised, cloned, and sequenced as described previously (Takei et al., 1998) . A BLAST search of the public database indicated that DNA sequences of this fragment were identical to part of the IRF-5 gene (Harada et al., 1998) . Northern-blot analysis con®rmed that expression of the IRF-5 gene was remarkably increased by infection of Ad-p53, but not Ad-LacZ, in a timedependent manner ( Figure 1a) .
To determine whether IRF-5 is a direct target of p53, we searched for a p53-binding sequence(s) within the 15-kb genomic sequence containing the IRF-5 gene Accession number: AC025594) and found a potential p53-binding sequence (p53BS) in exon 2 (Figure 1b) . Eighteen of the 20 nucleotides of this p53BS matched the consensus p53-binding sequence proposed by elDeiry et al. (1992) .
To con®rm the interaction between p53 protein and the candidate sequence (p53BS), we performed an electrophoretic mobility-shift assay (EMSA) using a nuclear extract puri®ed from H1299 cells (lung carcinoma, the American Type Culture Collection) infected by Ad-p53. As shown in Figure 2a , p53BS . Oligonucleotides for p53BS were synthesized and annealed (p53BS sense, 5'-AGGCATGCCA-CAAGGCATGGT-3'; p53BS antisense, 5'-GACCATGCCTTG-TGGCATGCCT-3'). Nuclear extract puri®ed from H1299 cells infected by Ad-p53 were incubated with sonicated salmon sperm DNA, the g 33 PATP-labeled double-strand oligomer and, in some cases, with monoclonal anti-p53 antibodies, PAb421 (Oncogene Science, Cambridge, MA, USA) and/or PAb1801 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). p53BS bound to a protein contained in the nuclear extract (lane 1), and the band was supershifted in the presence of Pab421 (lane 2). The interaction was inhibited by unlabeled oligonucleotides corresponding to the p53BS (competitor DNA (self)) (lane 3), but not by non-speci®c oligonucleotides (competitor DNA (non-speci®c)) (lane 4). The band was super-super-shifted by an addition of another anti-p53 antibody, Pab1801 (lane 5). (b) Luciferase assay. Oligonucleotides for two copies of p53BS (BS sense and antisense) and a onenucleotide-exchanged mutant of each of them (mt-BS sense and antisense) were designed as follows: BS sense, 5'-CGCGTAGG-CATGCCACAAGGCATGGTCAGGCATGCCACAAGGCAT-GGTCC-3'; BS antisense, 5'-TCGAGGACCATGCCTTGTGG-CATGCCTGACCATGCCTTGTGGCATGCCTA-3'; mt-BS sense, 5'-CGCGTAGGCATTCCACAAGGCATGGTCAGGCA-TGCCACAAGGCATTGTCC-3'; and mt-BS antisense, 5'-TCGAGGACCATGCCTTGTGGAATGCCTGACCATGCCTT-GTGGAATGCCTA-3'. These oligomers were annealed and ligated into pGL3-promoter vectors (Promega, Madison, WI, USA) to produce pGL3-BS and pGL3-mt-BS. H1299 cells were co-transfected with 1 mg each of pGL3-BS, pGL3-mt-BS, or pGL3-promoter vector and wild-type p53 expression vector (wtp53), mutant-type p53 expression vector (mt-p53), or pcDNA3.1 vector in combination with 1 mg of pRL-TK vector. 48 h after transfection, the cells were lysed in a passive lysis buer (Promega) and the Dual Luciferase system (Promega) was applied. Luciferase activities of pGL3-BS and pGL3-mt-BS were indicated as a fold induction relative to the activity of reporter vector without insertion of the p53-binding sequence bound to a protein contained in the nuclear extract (lane 1), and the band was super-shifted in the presence of mouse monoclonal anti-p53 antibody Pab421, indicating that p53BS bound to the p53 protein (lane 2). This evidence was further clari®ed by speci®c competition with self-DNA but not with non-speci®c Then to examine p53-dependent transcriptional activity of p53BS, we performed a heterologous reporter assay. As shown in Figure 2b , luciferase activity of pGL3-BS was enhanced more than 15-fold by co-transfection with wild-type p53 expression vector than by co-transfection with either mutant-type (R273H) p53 expression vector or mock vector. pGL3-mtBS vector that included a point mutation within p53BS revealed no enhancement of luciferase activity by co-transfection with wild-type p53 expression vector (Figure 2b ).
Moreover, we were able to show that IRF-5 mRNA was induced in response to DNA damage caused by either adriamycin or g-radiation in NHDF4042 cells (data not shown) and MCF7 cells (Figure 3 ) containing wild-type p53 (p53+/+), but not in H1299 cells (p537/7) (Figure 3 ). Taken together, these results clearly indicated that IRF-5 is indeed a direct target for p53.
To examine the eect of IRF-5 on cell growth, we performed colony-formation assays using expression vectors (sense-IRF5-FLAG or sense-IRF5) designed to express IRF-5 protein with or without a FLAG tag at the C-terminal. As a negative control we also prepared an expression vector in which the entire coding region of IRF-5 was inserted in the anti-sense direction (antisense-IRF5). Each of these vectors was transfected into A549 (lung cancer), or HCT116 (colorectal cancer) cells. Expression of IRF-5 protein after transfection with sense-IRF5-FLAG vector was con®rmed by immunoblotting, using mouse anti-FLAG monoclonal antibody (Kodak, data not shown). After 2 weeks of incubation in geneticin-containing media, ectopic expression of IRF-5 had reduced the numbers of colonies in these cell lines (Figure 4) . Similar results were obtained when we used sense-IRF5-FLAG expression vector (data not shown), suggesting that IRF-5 might play a role in cell growth control for some tissues outside of hematopoietic cells.
IRF-5 protein consists of 504 amino acids with a predicted molecular weight of 57 kDa (Accession number: AAA96056). It possesses about 30 ± 40% amino-acid identity to IRF-1, including the N-terminal portions containing DNA-binding domains ( Figure 5 ). IRFs are thought to be transcription factors that also play multiple roles, speci®cally as regards host defenses against various stimuli (Harada et al., 1998; Pitha et al., 1998) . They constitute a protein family of which more than ten members have been reported so far, including IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, interferon consensus sequence-binding protein (ICSBP), and interferon-stimulated gene factor 3g (ISGF3g) (Harada et al., 1998; Pitha et al., 1998) . IRF-1 regulates the interferon system by binding to a speci®c DNA sequence in target genes, and also regulates cell growth, i.e., functioning as a tumor suppressor (Tanaka et al., 1994) . IRF-3 plays a defensive role against genotoxic stresses (Kim et al., 1999) .
On multi-tissue Northern blots, two major transcripts of approximately 3.0 and 2.4 kb were highly expressed in spleen and peripheral blood lymphocyte (data not shown). The speci®c expression of this gene in lymphoid tissues indicates that it might be involved in the immune system, as are IRF-4 and ICSBP Driggers et al., 1990) . Therefore IRF-5 might play a role in signal transduction pathways that mediate either the protection or apoptosis of aected cells in the defensive responses induced by a speci®c genotoxic stress such as viral infection.
IRF-1 functions as a tumor suppressor by activating transcription of p21/WAF1 and ICE, and it also regulates cell-cycle arrest and apoptosis in response to various genotoxic stresses such as viral infection and genotoxins (Tamura et al., 1995; Tanaka et al., 1996) . Indeed, over-expression of IRF-5 in some cancer cells revealed the signi®cant growth-suppressive eect (Figure 4) . Although the function of IRF5 remains to be established, it might also be involved in tumor suppression in a p53-dependent manner.
